Table 2.

Results of base-case analysis and scenario analysis.

Drug	OS			Only PFS			Total
	Cost(95%CI)	Life-years	Utility(95%CI)	Cost(95%CI)	Life-years	Utility(95%CI)	Increment cost(95%CI)	Increment utility(95%CI)	ICER(95%CI)
base-case analysis
Chemotherapy	18,071.13 (18,055.61-18,093.51)	1.323	0.871 (0.870-0.872)	9,177.51 (9,169.85-9,189.65)	0.726	0.482 (0.481-0.483)	——	——	——
Sintilimab plus chemotherapy	43,636.61 (43,603.14-43,679.08)	2.782	1.712 (1.710-1.714)	22,691.80 (22,673.36-22,711.76)	1.338	0.900 (0.898-0.901)	25,565.48 (25,546.61-25,586.48)	0.841 (0.840-0.842)	30,409.44 (30,343.93-30,534.52)
scenario analysis
Chemotherapy	20,783.76 (20,741.69-20,797.99)	1.522	1.002 (1.001-1.004)	11,606.04 (11,598.02-11,614.03)	0.904	0.598 (0.596-0.599)	——	——	——
Sintilimab plus chemotherapy	40,065.40 (39,999.90-40,089.46)	2.523	1.598 (1.595-1.600)	30,775.25 (30,724.66-30,794.23)	2.005	1.267 (1.264-1.270)	19,281.64 (19,256.47-19,293.21)	0.595 (0.594-0.597)	32,376.78 (32,277.35-32,497.35)

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; PFS, progression-free survival; OS, overall survival; CI, confidence interval.

Unit of cost is USD; unit of utility is QALY.

95% confidence intervals of the life-years are not provided, since the input survival rate is fixed.